Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK. Bischoff J, et al. HIV Med. 2018 Apr;19(4):299-307. doi: 10.1111/hiv.12579. Epub 2018 Jan 25. HIV Med. 2018. PMID: 29368456 Free article.
Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?
Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group. Bischoff J, et al. J Clin Gastroenterol. 2020 Feb;54(2):192-199. doi: 10.1097/MCG.0000000000001189. J Clin Gastroenterol. 2020. PMID: 30789853
Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART.
Dold L, Nielsen MJ, Praktiknjo M, Schwarze-Zander C, Boesecke C, Schierwagen R, Mohr R, Wasmuth JC, Jansen C, Bischoff J, Rockstroh JK, Karsdal MA, Spengler U, Trebicka J, Leeming DJ. Dold L, et al. Among authors: bischoff j. PLoS One. 2019 Jul 11;14(7):e0219526. doi: 10.1371/journal.pone.0219526. eCollection 2019. PLoS One. 2019. PMID: 31295293 Free PMC article.
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19.
Krämer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-García R, Schulte-Schrepping J, Kaiser KM, Rieke GJ, Bischoff J, Monin MB, Hoffmeister C, Schlabe S, De Domenico E, Reusch N, Händler K, Reynolds G, Blüthgen N, Hack G, Finnemann C, Nischalke HD, Strassburg CP, Stephenson E, Su Y, Gardner L, Yuan D, Chen D, Goldman J, Rosenstiel P, Schmidt SV, Latz E, Hrusovsky K, Ball AJ, Johnson JM, Koenig PA, Schmidt FI, Haniffa M, Heath JR, Kümmerer BM, Keitel V, Jensen B, Stubbemann P, Kurth F, Sander LE, Sawitzki B; Deutsche COVID-19 OMICS Initiative (DeCOI); Aschenbrenner AC, Schultze JL, Nattermann J. Krämer B, et al. Among authors: bischoff j. Immunity. 2021 Nov 9;54(11):2650-2669.e14. doi: 10.1016/j.immuni.2021.09.002. Epub 2021 Sep 4. Immunity. 2021. PMID: 34592166 Free PMC article.
434 results